Global Biologics Market to grow at a CAGR of 9.59% by 2030, Evaluates DelveInsight | GlaxoSmithKline, Eli Lilly & Company, F. Hoffmann-La Roche Ltd, AbbVie Inc., Amgen Inc, Sanofi, Merck & Co., Inc, Novo Nordisk, Novartis AG, Pfizer Inc, AstraZeneca

According to DelveInsight's analysis, The biologics market is experiencing significant growth due to several key factors, including the rising incidence of autoimmune diseases like rheumatoid arthritis, a growing number of cancer cases, increasing prevalence of infectious and genetic disorders, and ongoing advancements and innovations in biologics product development.

DelveInsight's "Biologics Market Insights, Competitive Landscape and Market Forecast-2030" report provides the current and forecast market outlook, forthcoming device innovation, challenges, market drivers and barriers. The report also covers the major emerging products and key Biologics companies actively working in the market.

To know more about why North America is leading the market growth in the Biologics market, get a snapshot of the report Biologics Market Trends
https://www.delveinsight.com/sample-request/biologics-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Biologics Overview
Biologics are advanced medical products derived from living organisms. They include a wide range of treatments such as vaccines, blood components, gene therapies, and monoclonal antibodies. Unlike traditional drugs made through chemical synthesis, biologics are typically large, complex molecules produced using biotechnology methods. These therapies are designed to target specific components of the immune system and are commonly used to treat chronic diseases like cancer, autoimmune disorders, and rare genetic conditions. Their precision and effectiveness make them a rapidly growing area in modern medicine.

DelveInsight Analysis: The global biologics market reached a valuation of USD 333.10 billion in 2023 and is projected to grow at a CAGR of 9.59% between 2024 and 2030, eventually surpassing USD 577.03 billion by 2030.

Biologics Market Insights
Geographically, North America is projected to dominate the global biologic drugs market, largely due to its strong emphasis on developing therapies for rare diseases with orphan drug status, along with the increasing incidence of cancer and favorable regulatory frameworks. Additionally, factors such as high disposable income, advanced healthcare infrastructure, greater awareness of innovative treatments, and widespread insurance coverage are expected to further drive market growth in the region.

To read more about the latest highlights related to Biologics, get a snapshot of the key highlights entailed in the Biologics
https://www.delveinsight.com/report-store/biologics-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Recent Developments in the Biologics Market Report
• In October 2021, The US FDA has granted approval to Genentech, Inc.'s atezolizumab (Tecentriq) for use as an adjuvant therapy in patients with stage II to IIIA non-small cell lung cancer (NSCLC) following surgical resection and platinum-based chemotherapy.
• In August 2021, Bristol Myers Squibb was granted conditional marketing authorization by the European Commission for Abecma (idecabtagene vicleucel) to treat adult patients with relapsed and refractory multiple myeloma. Abecma is a first-in-class CAR T cell immunotherapy targeting B-cell maturation antigen (BCMA).
• In June 2021, The US FDA granted accelerated approval to Biogen Inc.'s Aduhelm (aducanumab) for the treatment of Alzheimer's disease.
• Thus, owing to such developments in the market, rapid growth will be observed in the Biologics market during the forecast period

Key Players in the Biologics Market
Some of the key market players operating in the Biologics market include- GlaxoSmithKline, Eli Lilly & Company, F. Hoffmann-La Roche Ltd, AbbVie Inc., Amgen Inc, Sanofi, Merck & Co., Inc, Novo Nordisk, Novartis AG, Pfizer Inc, AstraZeneca, Bristol Myers Squibb., Regeneron Pharmaceuticals Inc., Gilead Sciences, Inc., Boehringer Ingelheim International GmbH., Genentech, Inc, Biogen., bluebird bio, Inc, Janssen Global Services, LLC,., Cellitron Group and others.

Which MedTech key players in the Biologics market are set to emerge as the trendsetter explore @ Key Biologics Companies
https://www.delveinsight.com/sample-request/biologics-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Covid-19 Impact Analysis on the Biologics Market Landscape
The biologics market was among the few sectors that experienced positive growth during the COVID-19 pandemic. While global lockdowns disrupted manufacturing in many industries, the pressing need to develop COVID-19 vaccines created significant opportunities for biopharmaceutical companies. The emergency use authorization of the first COVID-19 vaccine-Pfizer-BioNTech-in late December 2020 marked a turning point, accelerating vaccine development and approvals worldwide.

In recent years, monoclonal antibodies have received approvals for a variety of conditions including migraine, rheumatoid arthritis, and HIV. With the emergence of the COVID-19 pandemic, efforts to develop targeted therapies have intensified. For example, in November 2021, Celltrion Group secured marketing authorization for Regkirona, a monoclonal antibody treatment for patients aged 12 and above who do not require supplemental oxygen but are at high risk of developing severe COVID-19.

Given their therapeutic benefits and expanding applications, monoclonal antibodies are anticipated to experience significant growth, thereby boosting the overall biologics market during the forecast period.

Scope of the Biologics Market Report
• Coverage: Global
• Study Period: 2021-2030
• Biologics Market Segmentation By Type: Cell-Based Biologics, Gene-Based Biologics, Monoclonal Antibodies, Vaccines, Recombinant Proteins, And Others
• Biologics Market Segmentation By Application Type: Oncology, Immunology, Infectious Diseases, Neurological Diseases, And Others
• Biologics Market Segmentation By Manufacturing Type: In-House And Outsourced
• Biologics Market Segmentation By Geography: North America, Europe, Asia-Pacific, and Rest of the World
• Key Biologics Companies: GlaxoSmithKline, Eli Lilly & Company, F. Hoffmann-La Roche Ltd, AbbVie Inc., Amgen Inc, Sanofi, Merck & Co., Inc, Novo Nordisk, Novartis AG, Pfizer Inc, AstraZeneca, Bristol Myers Squibb., Regeneron Pharmaceuticals Inc., Gilead Sciences, Inc., Boehringer Ingelheim International GmbH., Genentech, Inc, Biogen., bluebird bio, Inc, Janssen Global Services, LLC,., Cellitron Group and others
• Porter's Five Forces Analysis, Product Profiles, Case Studies, KOL's Views, Analyst's View

Interested in knowing how the Biologics market will grow by 2030? Click to get a snapshot of the Biologics Market Analysis
https://www.delveinsight.com/sample-request/biologics-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Table of Contents
1 Biologics Market Report Introduction
2 Biologics Market Executive summary
3 Regulatory and Patent Analysis
4 Biologics Market Key Factors Analysis
5 Porter's Five Forces Analysis
6 COVID-19 Impact Analysis on Biologics Market
7 Biologics Market Layout
8 Global Company Share Analysis - Key 3-5 Companies
9 Company and Product Profiles
10 Project Approach
11 Biologics Market Drivers
12 Biologics Market Barriers
13 About DelveInsight

Latest Reports by DelveInsight
• Global Kinase Inhibitor Market: https://www.delveinsight.com/report-store/global-kinase-inhibitor-in-autoimmune-diseases-market-insight
• Nerve Repair And Regeneration Devices- Market Insights: https://www.delveinsight.com/report-store/nerve-repair-and-regeneration-market
• Intracranial Pressure Monitoring Devices Market: https://www.delveinsight.com/report-store/intracranial-pressure-monitoring-devices-market
• Diabetic Wound Market: https://www.delveinsight.com/report-store/diabetic-foot-ulcers-dfus-market
• Sglt2 Inhibitors Market: https://www.delveinsight.com/report-store/sglt2-inhibitors-market
• Electroencephelographs Pipeline Insight: https://www.delveinsight.com/report-store/epilepsy-pipeline-insight

Contact Us
Gaurav Bora
info@delveinsight.com
+14699457679
www.delveinsight.com
Connect With Us at:
LinkedIn | Facebook | Twitter

About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing end-to-end comprehensive solutions to improve their performance.
Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve.

This release was published on openPR.